HBS sets sights on US human trial for platelet preservation technology
This article was originally published in Clinica
Executive Summary
After completing a second in vitro study of its technology for extending the shelf life of blood platelets, Human BioSystems (HBS) is preparing to submit an application to the US FDA within the next few months to test the method in human infusion studies.